DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Seckel syndrome 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSeckel syndrome 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for seckel syndrome 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RB binding protein 8, endonuclease (RBBP8) — RBBP8 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7BGF · 2.802 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Seckel syndrome is a rare autosomal recessive disorder with an estimated incidence of 1:10,000. It is characterised by severe pre- and postnatal growth retardation, microcephaly with intellectual disability, and specific dysmorphic features including a bird-headed appearance with beaked nose, receding forehead, prominent eyes and micrognathia. Additional abnormalities have been described in the cardiovascular, haematopoietic, endocrine, gastrointestinal and central nervous systems. The condition is clinically and genetically heterogeneous: two loci were mapped to chromosomes 3q22.1-q24 and 18p11.31-q11.2 by homozygosity mapping in consanguineous families, but a 2002 study excluded these loci in five consanguineous and one multiplex non-consanguineous Seckel syndrome families, as well as in two consanguineous families with type II osteodysplastic primordial dwarfism. The underlying genetic defects identified so far collectively point to impaired cell cycle control and DNA replication as the molecular basis.
A 2014 case report described a six-year-old boy with Seckel syndrome and aplastic anaemia who underwent allogeneic bone marrow transplantation from a ten-of-ten HLA matched unrelated donor. The patient was in good health with no further complications at day +771. The authors concluded that bone marrow transplantation is an acceptable therapeutic option for Seckel syndrome complicated by haematological alterations. No other interventions or drug treatments are reported in these abstracts.
The abstracts provide no data on survival rates, response rates, or sample sizes beyond single case reports. No drug is mentioned in any of the abstracts. What remains missing is any systematic trial of a pharmacological intervention, any patient stratification by genotype, and the funding needed to move from single-case haematological rescue to a broader evidence base for this heterogeneous disorder.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 2002 · 74 citations · open access
Clinical and genetic heterogeneity of Seckel syndrome
AbstractSeckel syndrome is a rare autosomal recessive condition belonging to the group of osteodysplastic primordial "dwarfism" and characterized by the association of 1) severe pre- and postnatal growth retardation, 2) microcephaly with mental retardation, and 3) specific dysmorphic features. Recently, two disease loci have been mapped to chromosomes 3q22.1-q24 and 18p11.31-q11.2, respectively, by homozygosity mapping in consanguineous families. Here, we report on the exclusion of these loci in five consanguineous and one multiplex nonconsanguineous Seckel syndrome families and in two consanguineous families presenting type II osteodysplastic primordial dwarfism. These results support the view that Seckel syndrome is a clinically and genetically heterogeneous condition.
Successful outcome of allogeneic stem cell transplantation in Seckel syndrome
AbstractSeckel syndrome is a rare autosomal recessive disease, genetically heterogeneous, characterized by short stature, prenatal microcephaly, intellectual disability, dysmorphic features, chromosomal instability, and hematological disorders. We report the case of a six-yr-old boy with Seckel syndrome and aplastic anemia who underwent successful allogeneic bone marrow transplantation from ten of ten HLA matched unrelated donor. Currently the patient is on D+771, in good health conditions and with no further complications. In conclusion, this case indicates that bone marrow transplantation is an acceptable therapeutic option for Seckel syndrome complicated by hematological alterations.
Zenodo (CERN European Organization for Nuclear Research) · 2017 · 1 citations · open access
Seckel Syndrome In A 9 Year Old Child
AbstractSeckel Syndrome first defined by Seckel in 1959, is a rare (incidence 1:10000) genetically heterogeneous, autosomal recessive disorder presenting at birth. This syndrome is characterised by a proportionate dwarfism of prenatal onset, severe microcephaly with a bird headed appearance (beaked nose, receding forehead, prominent eyes and micrognathia) and mental retardation in addition to the characteristics craniofacial dysmorphism and skeletal defects, abnormalities have been described in the cardiovascular hematopoietic, endocrine, gastrointestinal and central nervous system. Usually such patients have poor psychomotor development.
Oxford University Press eBooks · 2016 · 0 citations
Seckel Syndrome
AbstractSeckel syndrome belongs to the family of Microcephalic Primordial Dwarfisms (MPDs), a clinically heterogeneous group of conditions associated with growth retardation, microcephaly, characteristic skeletal features and additional abnormalities. Over the last decade or so the underlying genetic defects for some MPDs have started to emerge. So far, these defects collectively highlight the requirement for optimal cell cycle control and progression including DNA replication for normal human development. In this chapter I will overview the genes implicated in Seckel syndrome. I will detail the clinical presentation of this disorder; contrasting it to the other overlapping MPDs, and describe current models underlying the molecular pathogenesis of the associated genetic defects, highlighting their inter-related and associated biological impacts. But first, I will provide some background to illuminate the precise origin of Seckel syndrome. My intention here is to place its origin or more precisely, its evolution, into some context, with the aim of helping to explain why this condition has often been mis- and/or over-diagnosed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
